A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

December 17, 2024

Study Completion Date

June 18, 2029

Conditions
Wilson's Disease
Interventions
GENETIC

VTX-801

"The investigational medicinal product (VTX-801) is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene).~After reconstitution VTX-801 will be administered as a single dose intravenous (IV) administration per patient, at up to 3 different dose levels."

Trial Locations (10)

8200

Aarhus University Hospital, Aarhus

27157

Wake Forest School of Medicine, Winston-Salem

32803

Advent Health, Orlando

45147

University Hospital Essen, Essen

48109

University of Michigan Health System, Ann Arbor

72076

Universitätsklinikum Tübingen (UKT), Tübingen

75235

University of Texas Southwestern Medical Center, Dallas

95817

UC Davis Medical Center, Sacramento

06510

Yale University School of Medecine, New Haven

GU2 7XX

Royal Surrey County Hospital, Guildford

All Listed Sponsors
lead

Vivet Therapeutics SAS

INDUSTRY